gastrointestinal endoscopy News
-
New Research Shows Progression to Esophageal Cancer as Detected by WATS3D
A newly published study as lead article in Gastrointestinal Endoscopy shows that Barrett’s esophagus (BE) and dysplasia progress to esophageal cancer at similar, or even higher, rates when diagnosed by WATS3D (wide-area transepithelial sampling with three-dimensional analysis) as they do when diagnosed by conventional forceps biopsies. This study titled “Progression of ...
-
Avalon Healthcare Solutions’ Client BCBS of South Carolina Adds CDx Diagnostics as In-Network Lab
CDx Diagnostics, Inc. is pleased to announce that it has signed an agreement with laboratory benefits management provider Avalon Healthcare Solutions, Inc. of Tampa, Fla. The agreement means that CDx will be an in-network specialty anatomic pathology laboratory of Avalon client BlueCross BlueShield of South Carolina, and builds on Avalon’s positive medical policy for CDx’s proprietary ...
-
CDx Diagnostics’ WATS3D Receives “Medically Necessary” Designation from Highmark Health Plans
WATS3D, a diagnostic platform developed by CDx Diagnostics to empower physicians to detect Barrett’s esophagus (BE) and esophageal dysplasia, has been designated as medically necessary by Highmark Blue Cross Blue Shield plans in Delaware, Pennsylvania, and West Virginia. Clinically proven to significantly increase the detection rate of BE, pre-cancer, and cancerous cells in the esophagus ...
-
CDx Diagnostics’ WATS3D Participates in Highmark, Inc. Health Plans in Delaware, Pennsylvania, and West Virginia
WATS3D, an AI powered diagnostic platform developed by CDx Diagnostics to empower physicians to reliably detect Barrett’s esophagus (BE) and esophageal dysplasia to help prevent esophageal cancer, was designated as medically necessary by Highmark, Inc. health plans in Delaware, Pennsylvania, and West Virginia in Q4 2021. CDx Diagnostics is pleased to share, that effective immediately, ...
-
Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions
Clinical trial published in peer-reviewed journal demonstrates diagnostic yield from Cellvizio®significantly exceeds standard of care (84.1% vs 34.1%); use of Cellvizio drives overall change in clinical management - including need for continued surveillance or surgery - in 42.3% of cases Mauna Kea Technologies today announced a publication that demonstrates how Cellvizio positively impacts ...
-
Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated
LEXINGTON, Mass., February 1, 2021 — Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced the publication of clinical results from the investigator-initiated INSPIRE clinical trial conducted in collaboration with Fractyl. The results demonstrate that a majority of patients ...
-
Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. The chronic progression of IBD is characterized by periods of symptomatic relapses and symptom-free phases. During relapses, acute inflammation occurs in the bowel of IBD patients, leading to typical symptoms ...
-
Omega Medical Imaging Announces Installation of First AI Image-Guided Interventional Endoscopy System in Hawai’i
Sanford, Florida (July 28, 2021) — Omega Medical Imaging, the leading innovator in AI image-guided interventional systems for hospitals and healthcare facilities around the world, announced the installation of the E-View.AI interventional endoscopy system at the Pali Momi Medical Center in Hawai’i. The E-View.AI represents the first AI image-guided system in the state of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you